Psychedelics: What Will It Take To Get Them to Market?

9:00 AM - 10:00 AM (PDT), Thursday, June 16, 2022

The psychedelics industry has evolved from a stigmatized counterculture phenomenon to a scientifically robust industry. There is increasing acceptance of psychedelic drugs as a promising avenue for the development of new treatments of mental health disorders. Interest is being driven by their great clinical potential to treat conditions with high unmet medical needs including depression, substance-use disorders, and pain. The urgent need for new treatments in these areas has been exacerbated by the COVID-19 pandemic.


Clinical development programs are now underway following a standard regulatory route. Support from the FDA for the development of synthetic psychedelics as approved treatment options has added to the huge investor interest over the past 18 months, with VCs at the center of the investor boom. Forecasts suggest that investment in the psychedelics sector could reach $6.85 billion by 2027.

Moderator
photo
The Telegraph
Speakers
photo
Partner and Investor
Neo Kuma Ventures
photo
CEO
PrecisionLife
photo
Associate Professor
University of Nottingham
photo
Chief Scientific Officer
Delix Therapeutics, Inc.
photo
CEO & Director
Zylorion Health
photo
CMO
Beckley Psytech Ltd.